London
· Delayed Price · Currency is GBP · Price in USD Sangamo Therapeutics Statistics
Total Valuation
Sangamo Therapeutics has a market cap or net worth of GBP 194.82 million. The enterprise value is 185.51 million.
| Market Cap | 194.82M |
| Enterprise Value | 185.51M |
Important Dates
The next estimated earnings date is Wednesday, March 5, 2025.
| Earnings Date | Mar 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +13.03% |
| Shares Change (QoQ) | +5.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 204.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 6.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.84 |
| EV / Sales | 4.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.12 |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.35 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.24 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -154.94% and return on invested capital (ROIC) is -64.79%.
| Return on Equity (ROE) | -154.94% |
| Return on Assets (ROA) | -46.35% |
| Return on Capital (ROIC) | -64.79% |
| Revenue Per Employee | 96,332 |
| Profits Per Employee | -248,405 |
| Employee Count | 405 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +160.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +160.27% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 35.45 |
| Average Volume (20 Days) | 177,983 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.24 |
Income Statement
In the last 12 months, Sangamo Therapeutics had revenue of GBP 39.01 million and -100.60 million in losses. Loss per share was -0.52.
| Revenue | 39.01M |
| Gross Profit | -57.87M |
| Operating Income | -91.56M |
| Pretax Income | -100.61M |
| Net Income | -100.60M |
| EBITDA | -87.31M |
| EBIT | -91.56M |
| Loss Per Share | -0.52 |
Balance Sheet
The company has 29.25 million in cash and 20.69 million in debt, giving a net cash position of 8.56 million.
| Cash & Cash Equivalents | 29.25M |
| Total Debt | 20.69M |
| Net Cash | 8.56M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 29.20M |
| Book Value Per Share | 0.14 |
| Working Capital | 11.17M |
Cash Flow
In the last 12 months, operating cash flow was -85.30 million and capital expenditures -2.08 million, giving a free cash flow of -87.38 million.
| Operating Cash Flow | -85.30M |
| Capital Expenditures | -2.08M |
| Free Cash Flow | -87.38M |
| FCF Per Share | n/a |
Margins
Gross margin is -148.33%, with operating and profit margins of -234.69% and -257.86%.
| Gross Margin | -148.33% |
| Operating Margin | -234.69% |
| Pretax Margin | -257.89% |
| Profit Margin | -257.86% |
| EBITDA Margin | -223.80% |
| EBIT Margin | -234.69% |
| FCF Margin | n/a |
Dividends & Yields
Sangamo Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.03% |
| Shareholder Yield | -13.03% |
| Earnings Yield | -51.64% |
| FCF Yield | -44.85% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sangamo Therapeutics has an Altman Z-Score of -20.65. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.65 |
| Piotroski F-Score | n/a |